



Republic of the Philippines  
Department of Health  
**FOOD AND DRUG ADMINISTRATION**



**FDA ADVISORY**  
No. 2019-369-A

12 APR 2021

**TO: ALL HEALTHCARE PROFESSIONALS AND THE GENERAL PUBLIC**

**SUBJECT: Lifting the Advisory on the Registered Food Product ENZACTA PXP ROYALE SUPERCHARGER Dietary Supplement "Public Health Warning Against the Purchase and Consumption of the Unregistered Food Products and Food Supplements"**

The Food and Drug Administration (FDA) informs the public that the food product **ENZACTA ALFA PXP ROYALE SUPERCHARGER Polysaccharide Peptides Dietary Supplement** has been registered by the Market Authorization Holder (MAH) **UNITED ENZACTA ENTERPRISES INC.** in accordance to existing FDA rules and regulations.



Figure 1. Approved label of ENZACTA ALFA PXP ROYALE SUPERCHARGER Polysaccharide Peptides Dietary Supplement, FR-4000002481692 issued on 12 November 2021 valid until 12 November 2021

Civic Drive, Filinvest Corporate City, Alabang 1781 Muntinlupa, Philippines  
Trunk Line +63 2 857 1900  
Website: [www.fda.gov.ph](http://www.fda.gov.ph)

Fax +63 2 807 0751  
Email: [info@fda.gov.ph](mailto:info@fda.gov.ph)



Management System  
ISO 9001:2015



[www.tuv.com](http://www.tuv.com)  
ID 9105073396


Accordingly, the list released in FDA Advisory No. 2019-369 is hereby updated to remove the aforementioned food product.

The public is advised to always check if a food product or food supplement is registered with the FDA by using the **FDA Verification Portal feature** accessible at **<https://verification.fda.gov.ph>**. You may also look for the FDA Registration number on the product label, if available or simply type the name of the product.

To report any sale or distribution of unregistered food product, kindly email us through [ereport@fda.gov.ph](mailto:ereport@fda.gov.ph).

The public health warning imposed on the remaining products listed in FDA Advisory No. 20xx-xxxx shall remain to be upheld and shall not be affected by the issuance of this advisory. Furthermore, the issuance of this advisory shall not in any manner preclude this Office from issuing subsequent orders it may deem necessary and appropriate, should there be findings of any violation of the company to the existing laws, rules, and regulations.

Dissemination of this advisory to all concerned is hereby requested.

  
**ROLANDO ENRIQUE D. DOMINGO, MD**  
Director General



DTN 20210318110712